Levodropropizine

Levodropropizine (DF-526) is an orally active histamine receptor inhibitor, Levodropropizine is an effective and very well tolerated peripheral antitussive agent[1].

Product Specifications

CAS Number

[99291-25-5]

Product Name Alternative

(S) - (-) -Dropropizine; DF-526

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Histamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Endocrinology; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Levodropropizine.html

Purity

99.71

Solubility

DMSO : ≥ 50 mg/mL|H2O : 10 mg/mL (ultrasonic)

Smiles

OC[C@@H](O)CN1CCN(C2=CC=CC=C2)CC1

Molecular Formula

C13H20N2O2

Molecular Weight

236.31

Precautions

H302, H315, H319, H335

References & Citations

[1]Zanasi A, et al. Levodropropizine for treating cough in adult and children: a meta-analysis of published studies. Multidiscip Respir Med. 2015 May 31;10 (1) :19.|[2]Luo YL, et al. Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure. Inflamm Res. 2013 Dec;62 (12) :1053-61.|[3]Erdogan MA, et al. Levodropropizine suppresses seizure activity in rats with pentylenetetrazol-induced epilepsy. Epilepsy Res. 2019 Feb;150:32-37. |[4]Yamawaki I, et al. Levodropropizine reduces capsaicin- and substance P-induced plasma extravasation in the rat trachea. Eur J Pharmacol. 1993 Oct 12;243 (1) :1-6.